Amphiprotech
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A private biotech leveraging a proprietary protein engineering platform to develop next-generation antibodies and biologics.
OncologyImmunology
Technology Platform
A proprietary protein engineering platform that enhances the stability, solubility, and pharmacokinetic profile of antibody and biologic drug candidates.
Opportunities
Opportunity to out-license its platform technology or specific candidates to larger pharma companies seeking improved biologic modalities.
Risk Factors
Key risk is technological, as the novel protein constructs must demonstrate superior efficacy and safety in vivo to justify development.
Competitive Landscape
Faces intense competition in the antibody engineering space from global leaders and numerous Chinese biotechs, requiring clear technological differentiation.